09:49 AM EST - Critical Outcome Technologies Inc. : has executed a material transfer agreement with Dr. John Yoo, MD, FRCSC, FACS, and his team at the London Health Sciences Centre's London Regional Cancer Program and Western University, for the continued evaluation of COTI-2 for the treatment of patients with recurrent head and neck squamous cell cancer. Critical Outcome Technologies Inc.
shares V.COT are trading unchanged at $0.25.
